XML 76 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Business Acquisition - Additional Information (Detail) - USD ($)
 4 Months Ended 12 Months Ended
Dec. 23, 2020
Dec. 18, 2020
Sep. 14, 2020
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Business Acquisition [Line Items]            
Common stock, par value       $ 0.001 $ 0.001 $ 0.001
Goodwill       $ 48,648,000 $ 48,648,000  
Issuance of common stock in connection with conversion of Series X preferred stock, Shares         (3,796)  
Proceeds from issuance of common stock         $ 9,000,000 $ 9,676,000
Net loss and other comprehensive loss         24,314,000 $ 20,353,000
General and Administrative [Member]            
Business Acquisition [Line Items]            
Business acquisition costs         $ 2,900,000  
Series X1 Preferred Stock [Member] | Stock Purchase Agreement [Member]            
Business Acquisition [Line Items]            
Proceeds from issuance of common stock $ 9,000,000          
Series X1 Preferred Stock [Member]            
Business Acquisition [Line Items]            
Preferred stock, par value   $ 0.001   $ 0.001 $ 0.001 $ 0.001
Issuance of common stock in connection with conversion of Series X preferred stock, Shares   231,068        
Preferred stock, shares outstanding       108,070 108,070 0
Common Stock [Member]            
Business Acquisition [Line Items]            
Shares of common stock issued upon conversion of each share of preferred stock   12,837,056        
Common Stock [Member]            
Business Acquisition [Line Items]            
Issuance of common stock in connection with conversion of Series X preferred stock, Shares         210,888  
Shares of common stock sold 1,004,111       1,004,111  
Proceeds from issuance of common stock $ 9,000,000          
Common Stock [Member] | Series X1 Preferred Stock [Member] | Stock Purchase Agreement [Member]            
Business Acquisition [Line Items]            
Shares of common stock sold 1,004,111          
Anelixis [Member]            
Business Acquisition [Line Items]            
Business acquisition, date of acquisition     Sep. 14, 2020      
Common stock, par value     $ 0.001      
Goodwill     $ 48,649,000      
Business acquisition costs         $ 3,400,000  
Estimated fair value related to clinical development program     32,386,000      
Gain from forgiveness of debt excluded from pro forma combined financial information         655,000  
Other expenses excluded from pro forma combined financial information         $ 512,000 $ 395,000
Net loss and other comprehensive loss       $ 2,500,000    
Anelixis [Member] | In-Process Research and Development [Member]            
Business Acquisition [Line Items]            
Estimated fair value related to clinical development program     $ 32,400,000      
Anelixis [Member] | Series X1 Preferred Stock [Member]            
Business Acquisition [Line Items]            
Shares Issued to stockholders of acquiree     140,026      
Anelixis [Member] | Series X1 Preferred Stock [Member] | Stock Purchase Agreement [Member]            
Business Acquisition [Line Items]            
Preferred stock shares agreed to sell     199,112      
Preferred stock shares aggregate purchase price     $ 99,100,000      
Business combination additional commitments in equity financing     $ 9,000,000      
Preferred stock, par value   $ 0.001        
Anelixis [Member] | Common Stock [Member]            
Business Acquisition [Line Items]            
Shares Issued to stockholders of acquiree     175,488      
Shares of common stock issued upon conversion of each share of preferred stock     55.5556      
Anelixis [Member] | Common Stock [Member] | Series X1 Preferred Stock [Member] | Stock Purchase Agreement [Member]            
Business Acquisition [Line Items]            
Shares of common stock issued upon conversion of each share of preferred stock     55.5556